Teva reduces 2012 sales forecast - Marketwatch

The reduced forecast for branded drugs includes its outlook for leukemia drug Treanda and its women's health products. Teva recently reported its first-quarter profit jumped 41%, as strong sales of branded and generic medicines in the U.S. and ...

Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40 - StreetInsider.com

Brand product net sales of approximately $8.0 billion including estimated global net sales of the following products: -- COPAXONE® of $3.8 billion-- TREANDA® of $580 million-- Women’s Health products of $500 million-- ProAir® HFA of $430 million ...

What's Hot at ASCO This Year? - Medscape News

Bendamustine is a decades-old drug, but it was given a new lease on life in 2008 when it was approved (as Treanda, Cephalon) by the US Food and Drug Administration (FDA) for first-line use in chronic lymphocytic leukemia (CLL). However, the dose used in ...

Mixed Quarter from Teva - Zacks.com

Revenues benefited from the inclusion of Cephalon products – Provigil ($291 million), Treanda ($148 million) and Nuvigil ($84 million). Key branded product Copaxone posted global in-market sales of $941 billion, up 4%. Other products/segments that ...

Mixed Quarter from Teva - Analyst Blog - Boston Globe

Revenues benefited from the inclusion of Cephalon products – Provigil ($291 million), Treanda ($148 million) and Nuvigil ($84 million). Key branded product Copaxone posted global in-market sales of $941 billion, up 4%. Other products/segments ...

Strong growth at Teva as Yanai era ends - Chicago Tribune

The increase in branded products revenue was mainly due to the inclusion of Cephalon sales (mainly Provigil with $291 million in revenue, Treanda with $148 million and Nuvigil with $84 million). Most of Teva's major branded products also had strong revenue.